1 year clinical outcomes
| Prior PPM | (b) New PPM | (c) no PPM | (d) LBBB/no PPM | p Value | |||
|---|---|---|---|---|---|---|---|
| % (n) | % (n) | % (n) | % (n) | (a) vs (c) | (b) vs (c) | (c) vs (d) | |
| Mortality | |||||||
| All LVEF | 27.4 (158) | 26.3 (45) | 20.0 (319) | 27.7 (44) | 0.001 | 0.05 | 0.02 |
| LVEF >50% | 22.0 (61) | 24.2 (29) | 18.2 (211) | 30.2 (19) | 0.18 | 0.09 | 0.01 |
| LVEF 35–50% | 29.8 (51) | 34.3 (12) | 23.7 (67) | 37.5 (21) | 0.15 | 0.14 | 0.03 |
| LVEF <35% | 33.3 (46) | 22.2 (4) | 23.8 (41) | 9.8 (4) | 0.06 | 0.79 | 0.06 |
| Rehospitalisation | 22.1 (114) | 23.9 (37) | 17.8 (260) | 22.8 (32) | 0.04 | 0.03 | 0.12 |
| Mortality/Rehospitalisation | 39.0 (226) | 42.0 (72) | 31.9 (508) | 40.9 (65) | 0.002 | 0.003 | 0.01 |
| CV mortality | 13.5 (74) | 7.6 (12) | 8.4 (130) | 14.5 (22) | 0.001 | 0.68 | 0.01 |
| Stroke | 3.2 (17) | 3.5 (6) | 5.8 (88) | 6.6 (10) | 0.02 | 0.28 | 0.61 |
| Afib on ECG | 12.3 (44) | 17.1 (18) | 20.7 (219) | 20.4 (21) | 0.0004 | 0.39 | 0.94 |
| NYHA class III | 11.3 (44) | 9.3 (11) | 10.7 (125) | 7.5 (8) | 0.76 | 0.64 | 0.30 |
| NYHA class IV | 2.0 (8) | 0.0 (0) | 1.9 (22) | 0.0 (0) | 0.84 | 0.13 | 0.15 |
| MI | 1.1 (6) | 2.1 (3) | 1.6 (25) | 4.3 (6) | 0.38 | 0.83 | 0.04 |
Variables included in propensity matching included age, sex, STS score, body mass index, diabetes, hyperlipidaemia, smoking, hypertension, CAD, MI, PCI, CABG, PVD, cardiomyopathy, renal disease, valve size, mean aortic valve gradient and aortic valve area.
The mortality, rehospitalisation, mortality/rehospitalisation, and cardiovascular mortality rates were not significantly different between prior PPM and LBBB/no PPM.
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CV, cardiovascular; LBBB, left bundle branch block; MI, myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; PVD, peripheral vascular disease; STS, Society of Thoracic Surgeons.